Obesity treatment in South Africa doesn’t look the way it did ten years ago. The conversation about weight—long dominated by diets, willpower, and shame—now often ends with a prescription, if medically suitable. More people are asking their doctors about Wegovy and Mounjaro for weight management. And yes, more doctors are having that conversation back.

Both are once-weekly injectable medications that help regulate appetite and support weight loss. But are they the same thing? Which one is better? What’s the real difference? Here’s a breakdown of four ways they compare, so you can walk into that doctor’s consultation better informed.

How They Work: One Hormone vs Two

GLP-1 is a natural hormone your gut releases after a meal. It tells your brain you’re satisfied and keeps blood sugar stable. Wegovy is a medication that mimics this hormone to help with weight loss. Mounjaro does the same but also targets a second hormone called GIP. GIP works alongside GLP-1 to boost insulin and enhance appetite control in a complementary way. Together, they create a stronger signal to the body to store less fat.

This explains why some patients achieve greater weight loss with Mounjaro compared with Wegovy under medical care. A healthcare provider will decide the best option after review of the medical history and expected treatment response.

Weight Loss Results: What the Trials Show

Clinical trials and head-to-head studies have indicated that Mounjaro is more efficient for weight loss than Wegovy.

In the SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, participants on Mounjaro lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% on Wegovy. However, a higher dose of Wegovy (7.2 mg) studied in the 2025 STEP UP trial showed that adults with obesity lost around 21% of body weight over the same period. At standard doses, Mounjaro leads. At the newer, higher Wegovy dose, the gap narrows considerably.

Approval Status in South Africa

Wegovy launched in South Africa in August 2025 and is the first GLP-1 medication formally approved here for weight management. Mounjaro launched in December 2024 as a diabetes treatment, and SAHPRA only gave it the green light for weight loss in October 2025. So for a period, doctors who prescribed Mounjaro for weight loss were doing so “off-label” — outside its official, approved purpose. Both now hold full approval for weight management in South Africa.

Medical Aid Coverage: What You Can Expect

Mounjaro has official registration for both diabetes and weight loss in South Africa, so schemes may cover it under the Chronic Illness Benefit — but only for members with type 2 diabetes who meet strict clinical criteria. Wegovy is registered solely for weight management, and because obesity is not classified as a Prescribed Minimum Benefit condition, schemes are not obligated to cover it. Members must either pay out of pocket or use their Savings Benefit, if available on their plan.

Frequently asked questions about Wegvy vs Mounjaro

What is the best medication for weight loss in South Africa?

There is no single “best” medication for everyone, but two leading options are Wegovy (semaglutide) and Mounjaro (tirzepatide). Wegovy is specifically approved for weight loss in South Africa and typically leads to around 15–20% body weight reduction when combined with lifestyle changes.

Mounjaro is often considered more potent because it targets two hormones (GLP-1 and GIP), which may result in greater weight loss in some patients, although it is sometimes prescribed off-label for weight management.

In practice, the “best” option depends on your BMI, medical history, cost, and whether you also have type 2 diabetes.

What is similar to Ozempic in South Africa?

The closest equivalent to Ozempic is Wegovy, as both contain the same active ingredient, semaglutide. The difference is that Wegovy is formulated at higher doses and is specifically approved for weight loss, while Ozempic is approved for diabetes but may be prescribed off-label for weight loss.

Another alternative is Mounjaro, which works differently but produces similar or greater weight-loss effects due to its dual-hormone action.

What is the generic name for Mounjaro?

The generic name for Mounjaro is tirzepatide, a dual GLP-1 and GIP receptor agonist used to regulate appetite, blood sugar, and metabolism.

How much does the Mounjaro injection cost in South Africa? 

The cost of Mounjaro in South Africa varies depending on dosage and provider. Typical pricing ranges from about R3,600 to R8,100 per month, with many patients paying around R4,000 to R4,600 monthly for standard doses.

Some structured programmes offer lower entry pricing, starting from roughly R2,500 to R5,100 per month, depending on support and dosage.

Zapmed’s cost starts from R1940 cash (R799 service fee plus medication starting point price).

Our subscription service is available from R1410 per month, cash (R450 subscription fee plus the medication’s starting point price).

Are medical weight loss treatments covered by South African medical aid?

Generally, no. Medical aids do not usually cover GLP-1 medications for weight loss, because obesity is not classified as a Prescribed Minimum Benefit (PMB).

Some schemes may cover these medications only for type 2 diabetes, and often under strict conditions.
Disclaimer: The information in this article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition.